JPS63233785A - Novel 3alpha-hydroxysteroid dehydrogenase and production thereof - Google Patents
Novel 3alpha-hydroxysteroid dehydrogenase and production thereofInfo
- Publication number
- JPS63233785A JPS63233785A JP62069598A JP6959887A JPS63233785A JP S63233785 A JPS63233785 A JP S63233785A JP 62069598 A JP62069598 A JP 62069598A JP 6959887 A JP6959887 A JP 6959887A JP S63233785 A JPS63233785 A JP S63233785A
- Authority
- JP
- Japan
- Prior art keywords
- enzyme
- hydroxysteroid dehydrogenase
- 3alpha
- molecular weight
- ability
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710172561 3alpha-hydroxysteroid dehydrogenase Proteins 0.000 title claims abstract description 12
- 102100024089 Aldo-keto reductase family 1 member C2 Human genes 0.000 title claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- -1 steroid compounds Chemical class 0.000 claims abstract description 9
- 238000001962 electrophoresis Methods 0.000 claims abstract description 8
- 241000186321 Cellulomonas Species 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 244000005700 microbiome Species 0.000 claims abstract description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 5
- 229920002401 polyacrylamide Polymers 0.000 claims abstract description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract 3
- 239000008363 phosphate buffer Substances 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 5
- 102000011145 Hydroxysteroid Dehydrogenases Human genes 0.000 claims 1
- 108010062875 Hydroxysteroid Dehydrogenases Proteins 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 abstract description 6
- 239000007853 buffer solution Substances 0.000 abstract description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 description 73
- 108090000790 Enzymes Proteins 0.000 description 73
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 230000000694 effects Effects 0.000 description 19
- 239000000758 substrate Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 10
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 9
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 9
- 229930007503 menthone Natural products 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 229940041616 menthol Drugs 0.000 description 8
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 7
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical group C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 6
- 235000011130 ammonium sulphate Nutrition 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 5
- 239000004380 Cholic acid Substances 0.000 description 5
- 239000008351 acetate buffer Substances 0.000 description 5
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 5
- 235000019416 cholic acid Nutrition 0.000 description 5
- 229960002471 cholic acid Drugs 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 4
- 229950006238 nadide Drugs 0.000 description 4
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 3
- 102000007327 Protamines Human genes 0.000 description 3
- 108010007568 Protamines Proteins 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- 229940061641 androsterone Drugs 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 229940048914 protamine Drugs 0.000 description 3
- 238000005185 salting out Methods 0.000 description 3
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- WVYWICLMDOOCFB-UHFFFAOYSA-N 4-methyl-2-pentanol Chemical compound CC(C)CC(C)O WVYWICLMDOOCFB-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- OHLRLMWUFVDREV-UHFFFAOYSA-N ethyl 4-chloro-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)CCl OHLRLMWUFVDREV-UHFFFAOYSA-N 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- NFLGAXVYCFJBMK-BDAKNGLRSA-N (-)-menthone Chemical compound CC(C)[C@@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-BDAKNGLRSA-N 0.000 description 1
- AEELXMHQIJJMKP-QWWZWVQMSA-N (2r,3r)-3-sulfanylbutane-1,2,4-triol Chemical compound OC[C@@H](O)[C@H](S)CO AEELXMHQIJJMKP-QWWZWVQMSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-QHDNXLQLSA-N 17beta-hydroxyandrostan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC21 NVKAWKQGWWIWPM-QHDNXLQLSA-N 0.000 description 1
- PCWGTDULNUVNBN-UHFFFAOYSA-N 4-methylpentan-1-ol Chemical compound CC(C)CCCO PCWGTDULNUVNBN-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 1
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000108056 Monas Species 0.000 description 1
- GLZPCOQZEFWAFX-JXMROGBWSA-N Nerol Natural products CC(C)=CCC\C(C)=C\CO GLZPCOQZEFWAFX-JXMROGBWSA-N 0.000 description 1
- QQULCGKMWXVCDO-HLSXMHAQSA-N OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO.OC(=O)CC(O)(C(O)=O)CC(O)=O Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO.OC(=O)CC(O)(C(O)=O)CC(O)=O QQULCGKMWXVCDO-HLSXMHAQSA-N 0.000 description 1
- 230000010718 Oxidation Activity Effects 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 230000010757 Reduction Activity Effects 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000002299 affinity electrophoresis Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000011916 stereoselective reduction Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Landscapes
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野]
近年、酵素を産業上に利用する種々の試みが展開されて
いる。1つは酵素の基質特異性を利用して雑多な化合物
が混入している組成の中から特定の化合物の濃度を選択
的に測定する臨床診断用酵素として、また1つは従来の
エネルギー多消費型の化学反応工程に酵素を用いて省エ
ネルギープロセスを確立するためのバイオリアクターへ
の利用である。本゛発明中の酵素は、ステロイド化合物
の中ではアンドロステロン、デオキシコール酸、ケノデ
オキシコール酸およびコール酸などの3α−ヒドロキシ
ステロイド化合物に特異的に作用することから、血液中
の胆汁酸を測定する臨床診断用酵素としての利用が期待
される。また当該酵素は3α−ヒドロキシステロイド化
合物以外に、種々のカルボニル基を持つ化合物、例えば
シクロヘキサノンやメチルイソブチルケトンに作用し、
対応するアルコールに還元したり、さらにターメントン
を不斉還元して香料として有用なにメントールに変換で
きるので、バイオリアクターによる有用物質生産に利用
できる。[Detailed Description of the Invention] [Field of Industrial Application] In recent years, various attempts have been made to utilize enzymes industrially. One is as a clinical diagnostic enzyme that utilizes the enzyme's substrate specificity to selectively measure the concentration of a specific compound from among a mixture of miscellaneous compounds, and the other is as a conventional energy-intensive enzyme. It is used in bioreactors to establish energy-saving processes by using enzymes in chemical reaction processes. Since the enzyme of the present invention specifically acts on 3α-hydroxysteroid compounds such as androsterone, deoxycholic acid, chenodeoxycholic acid, and cholic acid among steroid compounds, it is useful in clinical trials for measuring bile acids in blood. It is expected to be used as a diagnostic enzyme. In addition to 3α-hydroxysteroid compounds, the enzyme acts on various compounds with carbonyl groups, such as cyclohexanone and methyl isobutyl ketone.
Termentone can be reduced to the corresponding alcohol or asymmetrically reduced to menthol, which is useful as a fragrance, so it can be used to produce useful substances using a bioreactor.
[従来の技術]
本発明中の酵素に類似の機能を持つ酵素としてシュード
モナス・テストステロニー ATCC11996の生産
する3α−ヒドロキシステロイド脱水素酵素(以下3α
−H8DHと略す)が知られている(例えばr P、1
.Marcus、 p、Ta1ayら、J、Biol、
Chem、、 190巻、 661−674頁。[Prior Art] As an enzyme having a similar function to the enzyme in the present invention, 3α-hydroxysteroid dehydrogenase (hereinafter referred to as 3α
-H8DH) is known (for example, r P, 1
.. Marcus, p. Talay et al., J. Biol.
Chem, vol. 190, pp. 661-674.
1955年」)。、3α−H5DHはアンドロステロン
、コール酸ナトリウム、コール酸やデ14°キシコール
酸などの、いわゆる3α−ヒドロキシステロイド化合物
に対して大きな活性を持っている。1955”). , 3α-H5DH has great activity against so-called 3α-hydroxysteroid compounds such as androsterone, sodium cholate, cholic acid and de14° xycholic acid.
[発明が解決しようとする問題点コ
酵素を産業上に使用する場合、安定性の高いことが要求
される。従来の3α−HS D Hは60℃、10分間
の加熱によって全(活性を失う。この様に熱安定性が低
いという問題点が解決されれば、すなわちもっと安定性
の高い酵素が開発されれば、その実用的価値がさらに高
まることが期待される。[Problems to be Solved by the Invention When coenzymes are used industrially, they are required to have high stability. Conventional 3α-HSDH loses all its activity when heated at 60°C for 10 minutes.If this problem of low thermostability could be solved, that is, a more stable enzyme could be developed. It is expected that its practical value will further increase.
本発明は、このような安定性の高い新規な3α−ヒドロ
キシステロイド脱水素酵素とその製造法を提供するもの
である。The present invention provides such a novel 3α-hydroxysteroid dehydrogenase with high stability and a method for producing the same.
[問題を解決するための手段]
従来の3α−H8DHよりも安定性が高い酵素を取得す
る目的で、土壌等から微生物のスクリーニングを行った
。その結果、セルロモナス属にaすると認められる一閃
株がその目的にかなった性質を有していることを見いだ
したものである。すなわちセルロモナス属に属し、新規
な3α−H3DH生産能を有する微生−?培養し、培養
物から新規な3α−H3DHを採取することを特徴とす
る新規な3α−HS D Hの製造法に関するものであ
る。[Means for solving the problem] In order to obtain an enzyme with higher stability than the conventional 3α-H8DH, microorganisms were screened from soil and the like. As a result, it was discovered that the Ichishu strain, which is recognized as a member of the genus Cellulomonas, has properties suitable for the purpose. That is, a microorganism belonging to the genus Cellulomonas and having a novel ability to produce 3α-H3DH. The present invention relates to a novel method for producing 3α-HSDH, which is characterized by culturing and collecting the novel 3α-H3DH from the culture.
本発明に係わる新規な3α−I(tDHの製造は当該酵
素生産菌を培地に培養することによって行われる。当該
酵素生産菌としては、−例として本発明者らが土壌中よ
り分離したセルロモナス・ツルバタに属する株が挙げら
れる。なお本閑の菌学的性質は第1表および第2表に示
すとおりである。The production of the novel 3α-I (tDH) according to the present invention is carried out by culturing the enzyme-producing bacteria in a medium. Examples of the enzyme-producing bacteria include Cellulomonas, which the present inventors isolated from soil. The mycological properties of Honkan are shown in Tables 1 and 2.
第1表セルロモナス・ツルバタ・KE31の一学的性質
形態的性質
肉汁寒天培地上(so”c)
Shr 長#(1〜2μ1)48h
r 短4(0,5〜Lμm)運動性
十
胞子形成 −
ダラム染色 十
培養的性質
直径1mmの円形で黄色コロニーを形成するゼラチン液
化 +〈弱い)
生理的性質
カタラーゼ +
オ牛シターゼ +(弱い)
カゼイン分解 十
セルロース分解性 十
キサンチンの分解 −
食塩耐性 7%以下 生育
10%以上 生育しない
クエン酸の利用 −
色素の菌体外生成 −
細胞壁分析 リジンを含む
生育の温度範囲 20〜45℃(33°Cが良好)
生育のpH範囲 6.5〜8.5(7,2が良好)
酸素に対する態度 通性嫌気性
第2表 炭素源の資化征°−′″
グリセリン + 酢酸 十アラビノ
ース + グルフン酸 十リボース
+ 乳酸 十グルコース +
プロピオン酸 十ガラクトース + クエン酸
−フルクトース + セロビオース
十以上の菌学的性質から分類学上、本菌株は 「E、5
tackebrandtら、 Zbl、 Bakt、
HYg、、 1. Abt、Or4gC3,401
−409頁、1982年」に記載されている七本菌を用
いて新規な3α−H3DHを製造する方法について述べ
る。Table 1 Physical properties of Cellulomonas tourbata KE31 Morphological properties On broth agar medium (so”c) Shr Length # (1-2μ1) 48h
r Short 4 (0,5-Lμm) motility
Decaspore formation - Durham stain Decacultural properties Gelatin liquefaction forming circular yellow colonies 1 mm in diameter + (weak) Physiological properties Catalase + Bovine citase + (weak) Casein decomposition Decacellulose decomposition Decomposition of dexanthin - Salt Resistance 7% or less Growth 10% or more Use of citric acid that does not grow - Extracellular production of pigment - Cell wall analysis Temperature range for growth including lysine 20-45°C (33°C is good)
Growth pH range 6.5-8.5 (7.2 is good)
Attitude towards oxygen Facultative anaerobic Table 2 Assimilation of carbon sources °−′″ Glycerin + Acetic acid Decarabinose + Glufonic acid Deca ribose
+ Lactic acid Decoglucose +
Propionic acid Decagalactose + Citric acid -Fructose + Cellobiose
Based on more than 10 mycological properties, this strain is taxonomically classified as “E, 5
tackebrandt et al., Zbl, Bakt,
HYg,, 1. Abt, Or4gC3,401
A novel method for producing 3α-H3DH using the Shichimoto bacterium described in 1982, p. 409 will be described.
培地は資化性炭素および窒素その他無機物、ビタミン、
アミ、°jm、酵母エキス等を含む微生物の培養に通常
用いられる培地が広く使用される。The medium contains assimilable carbon, nitrogen and other inorganic substances, vitamins,
Media commonly used for culturing microorganisms, including Ami, °jm, yeast extract, etc., are widely used.
炭素源として例えばグルコース、ガラクト−ス、アラビ
ノース、スクロース、フルクトース、ソルボース、ンル
ビトール、グリセリン、エタノール等が挙げられる。窒
素源として例えばペプトン、肉エキス、酵母エキス、コ
ーンステイープリカー。Examples of the carbon source include glucose, galactose, arabinose, sucrose, fructose, sorbose, nrubitol, glycerin, and ethanol. Nitrogen sources such as peptone, meat extract, yeast extract, cornstarch liquor.
麦芽エキス、硫酸アンモニウム、リン酸アンモニウム、
塩化アンモニウム等が挙げられる。無機塩として例えば
リン酸塩、マグネシウム塩、カルシウム塩等が挙げられ
る。Malt extract, ammonium sulfate, ammonium phosphate,
Examples include ammonium chloride. Examples of inorganic salts include phosphates, magnesium salts, calcium salts, and the like.
これらの成分を含む培地を用いて20〜45℃好ましく
は30〜35℃で、培地のp■は6.5〜8.5好まし
くはpl+7〜7.5で10〜100hr、微好気的条
件下で培養する。菌を培養して得られた培養物から当該
酵素を抽出するには、公知の種々の処理方法を用いるこ
とができる。例えば遠心分離あるいは、ろ過等の通常の
方法で菌体を分離したのち、生菌体あるいはアセトン乾
燥処理菌体、凍結乾燥処理菌体を自己消化、フレンチプ
レス、ダイノミル、超音波処理等によって細胞を破砕し
たのち菌体抽パ出液を得る。菌体抽出液から当該酵素を
分離・精製するには、硫安塩析(20〜8oz飽和画分
)しで得た沈澱物を1/30M トリス緩衝液(p H
7、0)に溶解し、脱塩後この抽出液をあらかじめ同じ
緩衝液で平衡化したDEAE−セファロース等の陰イオ
ン交換体充填カラムに通し、当該酵素を吸着させる。次
に同じ緩衝液中で塩化カリウム濃度を段階的に上昇させ
る溶出法によってクロマトグラフィーを行うと、塩化カ
リウム濃度0.1Mで本酵素は溶出される。当該酵素を
含む活性画分は、公知の種々の精製法、例えばゲルろ過
、アフィニティークロマトグラフィー、電気泳動法等に
よりさらに精製される。Using a medium containing these components, the temperature is 20-45°C, preferably 30-35°C, and the p■ of the medium is 6.5-8.5, preferably pl+7-7.5 for 10-100 hr, under microaerobic conditions. Cultivate under. Various known treatment methods can be used to extract the enzyme from the culture obtained by culturing the bacteria. For example, after separating the bacterial cells using a conventional method such as centrifugation or filtration, the cells can be separated by autolysis, French press, Dyno Mill, ultrasonic treatment, etc., using live bacterial cells, acetone-dried bacterial cells, or freeze-dried bacterial cells. After crushing, a bacterial cell extract is obtained. To separate and purify the enzyme from the bacterial cell extract, the precipitate obtained by salting out ammonium sulfate (20-8oz saturated fraction) was mixed with 1/30M Tris buffer (pH
After desalting, the extract is passed through a column packed with an anion exchanger such as DEAE-Sepharose, which has been equilibrated with the same buffer in advance, to adsorb the enzyme. Next, when chromatography is performed in the same buffer using an elution method in which the potassium chloride concentration is increased stepwise, the enzyme is eluted at a potassium chloride concentration of 0.1M. The active fraction containing the enzyme is further purified by various known purification methods, such as gel filtration, affinity chromatography, and electrophoresis.
[当該酵素の理化学的性質コ
本発明により製造される新規な3α−H3D)(の理化
学的性質を以下に示す。The physicochemical properties of the novel 3α-H3D produced by the present invention are shown below.
39作用
当該酵素はニコチンアミドアデニンジヌクレオチド(N
AD)の存在下(アルカリ条件が好ましい)で1モルの
5α−アントロスタン−3α−オールールなどの基質を
、1モルの5α−アントロスタン−3,17−ジオンお
よびにメントンにそれぞれ変換する。39 action The enzyme is nicotinamide adenine dinucleotide (N
AD) (alkaline conditions are preferred) converts 1 mole of a substrate such as 5α-antrostane-3α-oleur into 1 mole of 5α-antrostane-3,17-dione and menthone, respectively.
一方、還元型ニコチンアミドアデニンジヌクレオチド(
NADH)存在下(酸性条件が好ましい)では、1モル
の5α−アントロスタン−17β−オール−3−オン(
4,5−ジヒドロテストステロン)あるいは1−メント
ンなどの基質を、1モルの5α−アントロスタン−3,
17−ジオールおよび夕、メントールに変換する。その
他カルボニル基を持った種々の化合物を対応するアルコ
ールに変換し、さらにその逆反応も行う。On the other hand, reduced nicotinamide adenine dinucleotide (
NADH) (acidic conditions are preferred), 1 mol of 5α-antrostan-17β-ol-3-one (
Substrates such as 4,5-dihydrotestosterone) or 1-menthone are mixed with 1 mole of 5α-antrostane-3,
Convert to 17-diol and menthol. It converts various other compounds with carbonyl groups into the corresponding alcohols, and also performs the reverse reaction.
b、基質特異性
第3表に示したように、3位にケトンを持つステロイド
化合物や文、メントン、4−クロロアセト酢酸エチルな
どをNADHの存在下で還元する。しかし不飽和ケトン
を有する4−アンドロステン−3,17−ジオンやプレ
ドニソロンに対しては活性がない。b. Substrate specificity As shown in Table 3, steroid compounds having a ketone at the 3-position, menthone, ethyl 4-chloroacetoacetate, etc. are reduced in the presence of NADH. However, it has no activity against 4-androstene-3,17-dione and prednisolone, which have unsaturated ketones.
第3表 種々の基質に対するAり元能5α−アン)−
oXタン−17β−オール−3−オン 0.24
1005α−アンドnスタン−3,17−シ゛オ
ン 0.24 435β−7ンド
0スタン−3,17−シ゛オン 0.17
7ブaケ゛ステ0ン
0.16 0.054
−1ンド0ステン−3,17−v”オン
0.24 0フ゛レドニソロン
0.14
0トク0oアセト酢酸エチk
6.1° 251−へ゛ンテンー3−
オン 53°°4.8
3−へ°ンテンー2−オン
5 1.44−へAセン−3−
オン 45
6.22−オキフベンタン酸ナトリウム
14.5° 1.6オ
、メントン
2.4 0.3基質はエタノールに
溶解して(エタノールの最終濃度は10%)、1/15
M酢酸緩衝液(pH4,6)中、30℃で反応した。Table 3 A-reactive ability for various substrates 5α-an)-
oXtan-17β-ol-3-one 0.24
1005α-and n-stan-3,17-sion 0.24 435β-7and 0-stan-3,17-sion 0.17
7 block a cabinet stage 0
0.16 0.054
-1nd 0sten-3,17-v"on
0.24 0 Firednisolone
0.14
0toku0oethyl acetoacetate
6.1° 251-centen-3-
On 53°°4.8
3-hen-2-on
5 1.44-to Asen-3-
on 45
6.22-Sodium okifbentanoate
14.5° 1.6o, Menthong
2.4 0.3 Substrate is dissolved in ethanol (final concentration of ethanol is 10%) and 1/15
The reaction was carried out in M acetate buffer (pH 4, 6) at 30°C.
° 緩衝液中に完全溶解して反応した。° Completely dissolved in the buffer solution and reacted.
°°号スペンジ゛lンの状態で反応した。The reaction occurred in the state of the °° pendant.
また第41表1坪示すように3α位にヒドロキシル基を
有するステロイド化合物や種々のヒドロキシ化合物など
をNADの存在下で酸化した。5α−アントロスタン−
3α−オール−17−オンに対する活性が最も高いが、
類似の5α−アンドロスクン−3β−オール−17−オ
ンのような3β−オール構造のステロイドには全く作用
しなかった。Further, as shown in Table 41, steroid compounds having a hydroxyl group at the 3α position and various hydroxy compounds were oxidized in the presence of NAD. 5α-Anthrostane-
It has the highest activity against 3α-ol-17-one, but
It had no effect on steroids with a 3β-ol structure such as the similar 5α-androscun-3β-ol-17-one.
第4表 種々の基質に対する酸化能
5α−アンド0スタン−3α−オール−17−オン
0.24 1005α−Tンドロスタン−3α
、1フβ−シ゛オール 0.24 815
α−77)”oスタン−3β−オール−17−オン0.
24 0テ゛オ什コール酸
0.17 3.1
ケノテ゛オキノコール酸
0.17 2.1コール酸
0.17
0.5にメントール
2.5 0.14イ1ブ
0八°ノー& 8
00 0.254−メチル−2−へ°
ンタノーk 150”
4.9シクロへ1号ノール
自り;贈” 4 、
6(+、−)6−メチル−5−へブテンー2−オール
38° 10.4ネロール
3.3
2.6ケ゛ラニオール
3.3 0.18
基質はエタノールに溶解して(エタノールの最終濃度は
101)、1/15MビU燐酸緩衝液(pH8,8)中
、30℃で反応した。Table 4 Oxidizing capacity for various substrates 5α-and0 stan-3α-ol-17-one
0.24 1005α-T-drostane-3α
, 1-fluor β-thiol 0.24 815
α-77)”o stane-3β-ol-17-one0.
240 Teocholic acid
0.17 3.1
Chenoteochoncholic acid
0.17 2.1 Cholic acid
0.17
0.5 with menthol
2.5 0.14 I1 B 08° No & 8
00 0.254-methyl-2-h°
ntano k 150”
No. 1 nol to 4.9 cyclo
Self; gift” 4,
6(+,-)6-methyl-5-hebuten-2-ol
38° 10.4 Nerol
3.3
2.6 keraniol
3.3 0.18
The substrate was dissolved in ethanol (final concentration of ethanol was 101) and reacted at 30°C in 1/15M BiU phosphate buffer (pH 8.8).
° サスベンジ゛1ンの状態で反応した。° Reacted in a suspended state.
°°緩衝液中に完全溶解して反応した。°° It was completely dissolved in the buffer and reacted.
c、Km値(ミハエリ必定数)
当該酵素のに+n値は5α−アントロスタン−17β−
オール−3オンが0.29mMでありにメントンは14
.3*Mであった。いずれも0.15mMN A D
H存在下、1715M酢酸緩衝液(pH4,5)中、3
0℃で測定した。c, Km value (Michaeli constant) The +n value of the enzyme is 5α-antrostane-17β-
All-3-one is 0.29mM and menthone is 14
.. It was 3*M. Both are 0.15mM N A D
3 in 1715M acetate buffer (pH 4,5) in the presence of H
Measured at 0°C.
d、金属イオン等の影響
金属イオンおよびその他の添加物(すべて終濃度3++
M)が酵素活性に及ぼす影響を調べた。第5表に示すよ
うにPa5Cuイオンが阻害した。d, influence of metal ions, etc.Metal ions and other additives (all final concentration 3++
The effect of M) on enzyme activity was investigated. As shown in Table 5, Pa5Cu ions were inhibited.
(>・人1:/i、ff!1’)
第5表 金′属イオンその他添加物の影響MgCl2会
6H20100° CL15O4・51120 7
6CoSOa・1j120 96
り′リクン 105CaC12−
2tlzO95り゛リシルク゛リシン 105
ZnSOa・7H2095!/’チオスレイトール
99NaC1100β −メに′hブトエタノ
ール 96(Nun)gsOa 96
EDTA 100FeSO44H2067無
撚 100°無添加を100としたときの相対
値
e6反応至適pH
kメントンを基質として、NADHの存在下で反応至適
pnを調べた。至適pH−4,5〜5.5(1/15M
酢酸緩衝液中)であった。またNADの存在下で、5α
−アントロスタン−3α−オール−17−オンを基質と
した場合の反応至適pHは7.5〜8.5(1/15M
リン酸緩衝液およびトリス−■C1緩衝液)であった。(>・Person 1: /i, ff!1') Table 5 Effect of metal ions and other additives MgCl2 6H20100° CL15O4・51120 7
6CoSOa・1j120 96
Ri'rikun 105CaC12-
2tlzO95 lysyl lysine 105
ZnSOa・7H2095! /'thiothreitol
99NaC1100β-Meni'hButethanol 96(Nun)gsOa 96
EDTA 100FeSO44H2067 Untwisted 100° Relative value e6 when no addition is taken as 100 Optimum reaction pH k Using menthone as a substrate, the optimal reaction pn was investigated in the presence of NADH. Optimum pH-4.5-5.5 (1/15M
in acetate buffer). Also, in the presence of NAD, 5α
-The optimum pH for the reaction when anthrostan-3α-ol-17-one is used as a substrate is 7.5-8.5 (1/15M
phosphate buffer and Tris-■C1 buffer).
f、安定pH範囲
当該酵素はpH6〜8(1/15Mリン酸緩衝液中)で
30 ’C524hr放置しても安定である。またpH
7,0,30℃で1.100hr放置したとき、50%
の活性が残存している。f. Stable pH range The enzyme is stable at pH 6-8 (in 1/15M phosphate buffer) for 30'C524hr. Also pH
50% when left at 7,0,30℃ for 1.100hr
activity remains.
g、安定温度範囲
1/15M !7ン酸緩衝液(pH7,0)中で、温度
を変えて安定性を調べた。当該酵素は、60℃以下の温
度で2hr保温したとき失活は全く認められない。g, stable temperature range 1/15M! Stability was investigated in a hexaphosphate buffer (pH 7.0) at varying temperatures. No deactivation of the enzyme was observed when the enzyme was kept at a temperature of 60° C. or lower for 2 hours.
h、精製方法
精製方法を第6表に示す。菌体破砕後、プロタミン処理
、硫安分画、イオン交換クロマトグラフィーおよびアフ
ィニティークロマトグラフィーを行うことによって、電
気泳動的に均一な酵素を得ることができる。なお酵素活
性は0.24mM、 5α−アンFoスタンー1779
−オール−3−オフ、0.15+gMN A DHの存
在下、1/15M酢酸緩衝液(pH4,5)中で測定し
た。酵素の力価は30”C11分間に1MモルのNAD
Hを減少(340nmで追跡)させる量を1単位とした
。h. Purification method The purification method is shown in Table 6. After disrupting the bacterial cells, an electrophoretically homogeneous enzyme can be obtained by performing protamine treatment, ammonium sulfate fractionation, ion exchange chromatography, and affinity chromatography. The enzyme activity was 0.24mM, 5α-AnFo st-1779.
-ol-3-off, measured in 1/15M acetate buffer (pH 4,5) in the presence of 0.15+gMNA DH. Enzyme titer is 1 Mmol NAD in 11 minutes at 30"C.
The amount by which H was reduced (tracked at 340 nm) was defined as 1 unit.
酵素の精製結果を第10表にまとめた。The enzyme purification results are summarized in Table 10.
(ytT−化合)
箪6表 新規な3α−H8DIの精製方法画分
分画方法、条件
1、培養液
↓ 遠心分離、(9,OOOrpm、15分)
2JI体
↓ 菌体破砕、夕゛イノミル(10分
)↓ 遠心分離(1g、0OOrp+a、30
分)3、細胞抽出液
↓ プロタミン処理(0,25$)↓
硫安塩析(20〜8o飽和2)4、硫安塩析画分
↓ 透析(pH7,1、l/15M )リス緩
衝液)5、透析液
↓ DEAE−セフ丁ロース・ク
ロマトグラフィー6、活性画分(0,1MKCl溶出画
分)↓ Blue A・りo
7)り゛ラフィーフ、精製酵素(0,1M)[CI溶出
画分)1、分子量
ネイティブ・ポリアクリルアミド電気泳動に於ける当該
酵素の分子量は98,000であった。またSDS電気
泳動における分子量は24,000であった。従って当
該酵素は4つのサブユニットから成ると考えられる。(ytT-compound) Table 6 Novel purification method fractions of 3α-H8DI
Fractionation method, condition 1, culture solution ↓ centrifugation, (9,OOOrpm, 15 minutes)
2JI cells ↓ Cell disruption, Inomil (10 minutes) ↓ Centrifugation (1g, 0OOrp+a, 30
3. Cell extract ↓ Protamine treatment (0.25 $) ↓
Ammonium sulfate salting out (20-8o saturation 2) 4, Ammonium sulfate salting out fraction ↓ Dialysis (pH 7,1, l/15M) Lith buffer) 5, Dialysate ↓ DEAE-Seftyloose chromatography 6, Active fraction (0.1M KCl elution fraction) ↓ Blue A. Rio
7) Refill, purified enzyme (0.1M) [CI elution fraction] 1, molecular weight The molecular weight of the enzyme in native polyacrylamide electrophoresis was 98,000. Moreover, the molecular weight in SDS electrophoresis was 24,000. Therefore, the enzyme is thought to consist of four subunits.
j、紫外線吸収スペクトル 当該酵素の紫外線吸収スペクトルを第1図に示した。j, ultraviolet absorption spectrum The ultraviolet absorption spectrum of the enzyme is shown in FIG.
λmax : 275nm、3SOnmif :
260rv付近、 270nm付近腕、結晶構造および
元素分析
現在までのところでは晶出するに至らず、したがって元
素分析も行うことができない。λmax: 275nm, 3SOnmif:
Arms around 260 rv, around 270 nm, crystal structure, and elemental analysis Up to now, no crystallization has occurred, and therefore elemental analysis cannot be performed.
[当該酵素の新規性コ
a、基質特異性
シクロヘキサノンを還元する酵素は馬肝臓由来のアルコ
ール脱水素酵素[EC1,1,1,1]が知られている
。しかし当該酵素はエタノールに対する活性一方、当該
酵素は3α−ヒドロキシステロイドに対する活性が強く
、既知の3α−H5DIに類似している。しかし、シュ
ードモナス・テストステロニー由来の3α−H3D)I
(シグマ社製、A酵素と略す)やシュードモナス・プ
チダ由来の3α−H8DH(B酵素と略す)などの既知
の酵素と比較すると、第7表に示すように基質特異性に
違いが見られる。[Novelty of the Enzyme Core A, Substrate Specificity The enzyme that reduces cyclohexanone is known to be alcohol dehydrogenase derived from horse liver [EC1,1,1,1]. However, while the enzyme has activity against ethanol, it has strong activity against 3α-hydroxysteroids and is similar to the known 3α-H5DI. However, 3α-H3D)I from Pseudomonas testosteronii
(manufactured by Sigma, abbreviated as A enzyme) and 3α-H8DH derived from Pseudomonas putida (abbreviated as B enzyme), there are differences in substrate specificity as shown in Table 7.
第7表 既知酵素との基質特異性の比較1.5α−アン
トロスタン−
3α −オール−17−オン too
100 1002、 コール酸ナト
リウム 1.1 43
−”’3、 テ゛オ今シコール酸
3.1 18 3484
、 コール酸 0.
5 30 3705、4−メチル−2−へ°
ンタl−ル 4.9 0.3
−6、5α−γンドロスタンー
17β−オール−3−オン 100
100 −7、5α−アンド0スタ
ン−
3,17−シ゛オン 44
107 −8、4−り00アセト酢酸エ
チル 25 0.2 −
° シヱート′モナス・テストステロニー ATCC
11996由来の3α −■SD■゛° シュ・ト′モ
ナス・7°fり゛ KY4667 (特開昭53−9
9392から引用した)由来の3α−11SDI
°°°比較データなし
No1〜5:pH8,8における基質の酸化活性(No
l”1OO)No6〜11:pH4,5ニおける基質の
還元活性(No6−100)、:Th、v二・
t すb チ5.’q・−アントロスタン−3α−オー
ル−17−オン(アンドロステロン)の酸化活性を10
0としたとき、当該酵素が有するコール酸ナトリウム、
コール酸およびデオキシフール酸の酸化活性はA酵素や
B酵素に比べて低いが、4−メチル−ペンタノールに対
する酸化活性はA酵素より高い。一方、5α〜アントロ
スタン−17β−オール−3−オン(4,5−デヒドロ
テストステロン)の還元活性を100としたとき、当該
酵素の4−クロロアセト酢酸エチル還元活性はA酵素に
比べて100倍以上高い。このように基質特異性が大き
く異なるのは、それぞれの酵素のアクティブサイトに違
いがある、すなわち酵素のアミノ酸配列が異なっている
ことを強く示唆しており、これらの酵素は互いに違った
構造を有していると考えられる。Table 7 Comparison of substrate specificity with known enzymes 1.5α-antrostane-3α-ol-17-one too
100 1002, Sodium cholate 1.1 43
−”'3, Theo-sicolic acid
3.1 18 3484
, cholic acid 0.
5 30 3705, 4-methyl-2-°
Tartar 4.9 0.3
-6,5α-γandrostane-17β-ol-3-one 100
100 -7,5α-and0 stun-3,17-sion 44
107 -8,4-ri00ethyl acetoacetate 25 0.2 -
° Sheet' Monas Testosterone ATCC
11996-derived 3α −SD■゛° Shutomonas 7°fri゛ KY4667 (JP-A-53-9
3α-11SDI derived from 9392 (quoted from
l"1OO) No. 6 to 11: Reduction activity of substrate at pH 4, 5 (No. 6-100), : Th, v2. androsterone) oxidation activity to 10
When set to 0, the sodium cholate possessed by the enzyme,
Although the oxidizing activity of cholic acid and deoxyfuric acid is lower than that of enzyme A and enzyme B, the oxidizing activity of 4-methyl-pentanol is higher than that of enzyme A. On the other hand, when the reducing activity of 5α~anthrostan-17β-ol-3-one (4,5-dehydrotestosterone) is set as 100, the ethyl 4-chloroacetoacetate reducing activity of the enzyme is more than 100 times that of enzyme A. expensive. This large difference in substrate specificity strongly suggests that the active sites of each enzyme are different, that is, the amino acid sequences of the enzymes are different, and these enzymes have different structures. it seems to do.
b、立体選択的還元性
)メントンをA酵素で還元したときの生成物はにメント
ール:d−ネオメントール嵩1:2である。一方、当該
酵素を用いた場合はえメントール=d−ネオメントール
=9?:3であり、当該酵素の立体選択性はA酵素に比
べて高いことがわ泣R=:、!。:茫′::こ“
C9分子量・反応至適pH・熱安定性
分子m等について当該酵素と既知酵素との比較を行った
。第8表に示すように、本酵素はA酵素およびC酵素(
シニードモナス・スフエリカス由来の3α−II S
D II )とは異なった性質を持っていた。b. Stereoselective reduction) When menthone is reduced with enzyme A, the product has a volume of menthol:d-neomenthol of 1:2. On the other hand, when using the enzyme, menthol=d-neomenthol=9? :3, and the stereoselectivity of the enzyme is higher than that of enzyme A.R=:,! . :茫′::こ“ The enzyme was compared with known enzymes in terms of C9 molecular weight, optimum reaction pH, thermostable molecule m, etc. As shown in Table 8, this enzyme is similar to enzyme A and enzyme C. (
3α-II S from Cynidomonas sphaericus
D II) had different properties.
第8表 既知酵素との比較
分子量 98.000 47,000 16G
、000反応至適pH7,5〜8.5 11〜11.5
10〜10.5熱安定性”” 100 0
記載なし・° シヱードモナス・ テストス
テロニー由来°°ハ′チラス・スフエリカス由来(特開
昭54−157894から引用)°°°数値は1715
M リン酸緩衝液(pH7,0)中、60℃で10分間
保温した後の残存活性を示す。Table 8 Comparison molecular weight with known enzymes 98.000 47,000 16G
, 000 reaction optimum pH 7.5-8.5 11-11.5
10-10.5 Thermal stability"" 100 0
No description・° Derived from Sidomonas testosteroni ° ° Derived from Ha'tilus sphaericus (quoted from Japanese Patent Application Laid-open No. 157894-1983) ° ° ° Numerical value is 1715
M shows the residual activity after incubation at 60°C for 10 minutes in phosphate buffer (pH 7,0).
すなわち分子量は王者で大きく異なること、反応至適p
HはA酵素、C酵素ともに当該酵素に比ベアルカリ側に
:l護、1こと、また当該酵素は60°C110分間加
熱後も100%の活性が残存するが、A酵素は、全く活
性を失うので、熱安定性は当該酵素の方が高いこと(第
2図参照)などである。In other words, the molecular weight differs greatly depending on the king, and the optimum reaction p
Both enzyme A and enzyme C are on the alkaline side compared to the enzyme concerned: 1. Also, the enzyme concerned remains at 100% activity even after heating at 60°C for 110 minutes, but the enzyme A loses its activity at all. Therefore, the thermostability of the enzyme is higher (see Figure 2).
以上に記述したように、当該酵素は既知の3α−H3D
Hと比べて、5α−アントロスタン−3α−オール−1
7−オンに対して活性が高いという共通点があるが、基
質特異性、立体選択性、分子量、反応至適pH、熱安定
性において何れも違いが見られる。As described above, the enzyme is a known 3α-H3D
5α-Anthrostan-3α-ol-1 compared to H
Although they have a common feature of high activity toward 7-one, they all differ in substrate specificity, stereoselectivity, molecular weight, optimum reaction pH, and thermal stability.
従って当該酵素を新規の3α−H5DRと命名すること
が適当である。Therefore, it is appropriate to name the enzyme the novel 3α-H5DR.
地100mLを含む)に植菌し、48hr培養した。な
お培養時、誘導基質としてメントン(0,05mL)を
2回に分けて添加した(添加したメントンはエタノール
と体積比で1=1の混合液とした)。この培養液を2L
容ジャーファーメンタ−(同培地をIL含む)に移し、
回転数40Orpm、通気fio、05vvmで48’
h−r培養を行った。(containing 100 mL of soil) and cultured for 48 hours. During culture, menthone (0.05 mL) was added in two portions as an induction substrate (the added menthone was mixed with ethanol in a volume ratio of 1=1). 2L of this culture solution
Transfer to a jar fermenter (containing the same medium as IL),
48' at rotation speed 40Orpm, ventilation fio, 05vvm
An hr culture was performed.
メントンはフラスコ培養と同様の方法で分添した。Menthone was added in the same manner as flask culture.
次に培養終了液を、3OL容ジャーファーメンタ−(同
培地2OLを含む)に移し、200rpm、 i!I気
ff1o、05yvmで、さらに50hr培養を行った
。培養途中で100mLの25%D−アラビノースを4
回分添した。またメントンは前培養と同様エタノールと
の混合液25mLを4回分添した。この培養菌体を用い
て、第6表に示す方法によって、当該酵素の精製を行っ
た。精製過程を第10表にまとめた。Next, the cultured solution was transferred to a 3OL jar fermentor (containing 2OL of the same medium) and heated at 200 rpm, i. Cultivation was further carried out for 50 hours at 0.5 yvm. During the culture, add 100 mL of 25% D-arabinose to
I attached a batch. In addition, 25 mL of a mixture of menthone and ethanol was added four times as in the pre-culture. Using this cultured bacterial cell, the enzyme was purified by the method shown in Table 6. The purification process is summarized in Table 10.
第9表 培地組成
NHaNO30,1g Fe5Oa、7H2010n
gNa2HPO4,12H200,9g Na2Mo
O* 0.6vagKI12PO490mg
Mn5Oa、6H200,6mgMg5Oa、’1H2
00,1g Yeast Extract 1.0
gCaCl2.2H2050mg D−7ラヒ
゛ノース D、5g蒸留水100m1、
pH7,2
第10表 酵素精製結果
分画液 総活性 比活性 回収率unit(
υl、、 %
細胞抽出液 19300 0.40 1
00プロタミン処理液 16900 0.48
88硫安分画液 15600 0.6!l
81DEAE・セフ7o4溶出画分 9750
15.3 51BIueAケ゛ル溶出画分
8470 20.4 44実施例2
当該酵素は、メチルイソブチルカルビノールを基質に用
いた場合、NADHの再生を行うことができる。そこで
、補酵素再生系の存在下でトメントンから)メントール
の生産を行った。Table 9 Medium composition NHaNO30, 1g Fe5Oa, 7H2010n
gNa2HPO4,12H200,9g Na2Mo
O* 0.6vagKI12PO490mg
Mn5Oa, 6H200, 6mgMg5Oa, '1H2
00.1g Yeast Extract 1.0
gCaCl2.2H2050mg D-7 Rahinose D, 5g distilled water 100ml,
pH7,2 Table 10 Enzyme purification result fraction Total activity Specific activity Recovery rate unit (
υl,,% Cell extract 19300 0.40 1
00 Protamine treatment solution 16900 0.48
88 ammonium sulfate fractionated liquid 15600 0.6! l
81DEAE/Cef7o4 elution fraction 9750
15.3 51BIueA gel elution fraction
8470 20.4 44 Example 2 The enzyme can regenerate NADH when methylisobutylcarbinol is used as a substrate. Therefore, we produced menthol (from tomentone) in the presence of a coenzyme regeneration system.
実施例1で調製した精製酵素を0.11単位(1単位は
30℃、pH4,5の1/15M酢酸緩衝液中で、1分
間に1μモルのにメントールを生成する酵素量とするン
′およびNADHo、1μiをO,1IllL(7)
1/15M燐酸緩衝液(pH7,0)に溶解したものと
、A、メント:!”’O’、’1lllL(578μモ
ル)およびメチルイソブチルカルビノールO,1mL(
775μモル)とを混ぜて、30 ’Cで4hr反応を
行った。The purified enzyme prepared in Example 1 was added to 0.11 units (one unit is the amount of enzyme that produces 1 μmol of menthol per minute in 1/15M acetate buffer at 30°C and pH 4.5). and NADHo, 1μiO, 1IllL (7)
Dissolved in 1/15M phosphate buffer (pH 7,0) and A, Mento:! 'O', '1lllL (578 μmol) and methylisobutylcarbinol O, 1mL (
775 μmol) and reacted at 30'C for 4 hours.
反応後の液に0.6mLのへキサンを添加し、ヘキサン
相をガスクロマトグラフィーで分析した( )IR−1
0Mカラム、100℃、ヘリウム 50mL/+nfn
)。反応液中には添加したNADHのほぼ170倍モル
に相当するにメントール16.7gモルとメチルイソブ
チルケトン2o、8μモルが検出された。0.6 mL of hexane was added to the reaction solution, and the hexane phase was analyzed by gas chromatography ( )IR-1
0M column, 100℃, helium 50mL/+nfn
). In the reaction solution, 16.7 g mole of menthol and 8 μmol of 20 methyl isobutyl ketone were detected, corresponding to approximately 170 times the mole of NADH added.
第1図は当該酵素の紫外線吸収スペクトルを示す。第2
図は当該酵素(←・)および既知の3α−H5DH(シ
ヱードモナス・テストステミニ−由L o−ベフ
) の安定温度範囲を示す。何れも各温度で、1715
M燐酸緩衝液(pH7,0)中、10分間保温後の残存
活性を示す。FIG. 1 shows the ultraviolet absorption spectrum of the enzyme. Second
The figure shows the enzyme (←・) and the known 3α-H5DH (L o-befu from S. testosterini).
) indicates the stable temperature range. At each temperature, 1715
The residual activity after incubation for 10 minutes in M phosphate buffer (pH 7,0) is shown.
Claims (2)
システロイド脱水素酵素 (a)3位にオキソ基を有するステロイド化合物やカル
ボニル基含有化合物に対して還元能を有する。 (b)ネイティブ・ポリアクリルアミド電気泳動法で測
定した分子量が98,000であり、SDS電気泳動法
で測定した分子量が24,000である。 (c)pH6〜8(1/15Mリン酸緩衝液中)で30
℃、24hr放置した場合およびpH7で60℃、2h
r放置した場合何れも安定である。(1) Highly stable 3α-hydroxysteroid dehydrogenase having the following properties (a) It has the ability to reduce steroid compounds having an oxo group at the 3-position and carbonyl group-containing compounds. (b) The molecular weight measured by native polyacrylamide electrophoresis is 98,000, and the molecular weight measured by SDS electrophoresis is 24,000. (c) 30 at pH 6-8 (in 1/15M phosphate buffer)
℃, 24 hours and pH 7 at 60℃, 2 hours
All are stable when left alone.
−ヒドロキシステロイド脱水素酵素生産能を有する微生
物を培養し、該培養物から3α−ヒドロキシステロイド
脱水素酵素を採取することを特徴とする3α−ヒドロキ
システロイド脱水素酵素の製造方法。 (a)3位にオキソ基を有するステロイド化合物やカル
ボニル基含有化合物に対して還元能を有する。 (b)ネイティブ・ポリアクリルアミド電気泳動法で測
定した分子量が98,000であり、SDS電気泳動法
で測定した分子量が24,000である。 (c)pH6〜8(1/15Mリン酸緩衝液中)で30
℃、24hr放置した場合およびpH7で60℃、2h
r放置した場合何れも安定である。(2) 3α belonging to the genus Cellulomonas and having the following characteristics
- A method for producing 3α-hydroxysteroid dehydrogenase, which comprises culturing a microorganism capable of producing hydroxysteroid dehydrogenase and collecting 3α-hydroxysteroid dehydrogenase from the culture. (a) It has the ability to reduce steroid compounds and carbonyl group-containing compounds having an oxo group at the 3-position. (b) The molecular weight measured by native polyacrylamide electrophoresis is 98,000, and the molecular weight measured by SDS electrophoresis is 24,000. (c) 30 at pH 6-8 (in 1/15M phosphate buffer)
℃, 24 hours and pH 7 at 60℃, 2 hours
All are stable when left alone.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62069598A JPS63233785A (en) | 1987-03-24 | 1987-03-24 | Novel 3alpha-hydroxysteroid dehydrogenase and production thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62069598A JPS63233785A (en) | 1987-03-24 | 1987-03-24 | Novel 3alpha-hydroxysteroid dehydrogenase and production thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS63233785A true JPS63233785A (en) | 1988-09-29 |
JPH0323154B2 JPH0323154B2 (en) | 1991-03-28 |
Family
ID=13407431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP62069598A Granted JPS63233785A (en) | 1987-03-24 | 1987-03-24 | Novel 3alpha-hydroxysteroid dehydrogenase and production thereof |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS63233785A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109486896A (en) * | 2018-12-04 | 2019-03-19 | 南京工业大学 | A method of catalysis fractionation prepares Isoglycyrrhiza acid |
CN109486895A (en) * | 2018-12-04 | 2019-03-19 | 南京工业大学 | A method of catalysis fractionation prepares Isoglycyrrhiza acid |
-
1987
- 1987-03-24 JP JP62069598A patent/JPS63233785A/en active Granted
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109486896A (en) * | 2018-12-04 | 2019-03-19 | 南京工业大学 | A method of catalysis fractionation prepares Isoglycyrrhiza acid |
CN109486895A (en) * | 2018-12-04 | 2019-03-19 | 南京工业大学 | A method of catalysis fractionation prepares Isoglycyrrhiza acid |
Also Published As
Publication number | Publication date |
---|---|
JPH0323154B2 (en) | 1991-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH031949B2 (en) | ||
JPH0527395B2 (en) | ||
JPS61128887A (en) | Production of peroxidase | |
JPS63233785A (en) | Novel 3alpha-hydroxysteroid dehydrogenase and production thereof | |
US4061540A (en) | Cholesterol oxidaze and process for preparing same | |
US4463095A (en) | Process for producing α-glycerophosphate oxidase | |
JPH0460637B2 (en) | ||
JPH0249720B2 (en) | ||
JP3773283B2 (en) | D-Lactate dehydrogenase and method for producing the same | |
Akao et al. | Purification and properties of 3α-hydroxyglycyrrhetinate dehydrogenase of Clostridium innocuum from human intestine | |
JPH0218064B2 (en) | ||
JP2768473B2 (en) | Method for producing NADH oxidase | |
JPH07108219B2 (en) | Method for producing NADH oxidase | |
JP3150868B2 (en) | 6-Phosphogluconate dehydrogenase and its production | |
JP2966513B2 (en) | Method for producing peroxidase | |
Stournaras et al. | [48] 6-phospho-d-gluconate dehydrogenase from Pseudomonas fluorescens | |
JP3532937B2 (en) | Novel NADPH-dependent diaphorase having high heat resistance and method for producing the same | |
JPS61219384A (en) | Production of n-acylneuraminic acid aldolase | |
JP3649765B2 (en) | Novel glycerol kinase and process for producing the same | |
JPS5942888A (en) | Preparation of ester-bond hydrolase by microorganism | |
Warchol et al. | Metabolic changes in Clostridium absonum ATCC 27555 accompanying induction of epimerization of a primary bile acid | |
JPS6046953B2 (en) | Improved production method of choline oxidase | |
JPH06225755A (en) | Dextran sucrase-producing new microorganism and method for producing dextran sucrase with the microorganism | |
JP2801694B2 (en) | New enzyme | |
JPH0683668B2 (en) | Method for producing thermostable α-amylase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EXPY | Cancellation because of completion of term |